T Berg

Summary

Affiliation: Humboldt University
Country: Germany

Publications

  1. doi request reprint CD154, a marker of antigen-specific stimulation of CD4 T cells, is associated with response to treatment in patients with chronic HCV infection
    J F Möller
    Medizinische Klinik m S Hepatologie und Gastroenterologie, Charite Universitatsmedizin Berlin, CVK, Berlin Hepatologische Schwerpunktpraxis, Berlin, Germany
    J Viral Hepat 18:e341-9. 2011
  2. pmc Isoforms of retinol binding protein 4 (RBP4) are increased in chronic diseases of the kidney but not of the liver
    Simone K Frey
    Institute of Nutritional Science, University of Potsdam, Potsdam Rehbrucke, Germany
    Lipids Health Dis 7:29. 2008
  3. doi request reprint Tailored treatment for hepatitis C
    Thomas Berg
    Medical Department Hepatology and Gastroenterology, Charite, Campus Virchow Klinikum, Universitatsmedizin Berlin, Berlin, Germany
    Clin Liver Dis 12:507-28, vii-viii. 2008
  4. ncbi request reprint Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3
    Thomas Berg
    Charite Universitatsmedizin Berlin, Berlin, Germany
    Antivir Ther 13:17-22. 2008
  5. ncbi request reprint Distinct enzyme profiles in patients with cryptogenic cirrhosis reflect heterogeneous causes with different outcomes after liver transplantation (OLT): a long-term documentation before and after OLT
    Thomas Berg
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charite, Campus Virchow Klinikum, Humboldt Universitat zu Berlin, Germany
    Transplantation 74:792-8. 2002
  6. doi request reprint Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients
    Thomas Berg
    Universitatsklinikum Charite, Campus Virchow Klinikum, Universitatsmedizin Berlin, Berlin, Germany
    Hepatology 50:369-77. 2009
  7. ncbi request reprint Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial
    Thomas Berg
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Universitatsklinikum Charite, Campus Virchow Klinikum, Humboldt Universitat, Berlin, Germany
    Hepatology 37:1359-67. 2003
  8. ncbi request reprint Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin
    Thomas Berg
    Universitatsklinikum Charite, Campus Virchow Klinikum, Universitatsmedizin Berlin, Germany
    Gastroenterology 130:1086-97. 2006
  9. ncbi request reprint [Therapeutic challenges in viral hepatitis patients]
    A Bergk
    Medizinische Klinik m S Hepatologie und Gastroenterologie, Charite, Universitatsmedizin Berlin
    Dtsch Med Wochenschr 130:S218-20. 2005
  10. ncbi request reprint Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C
    T Berg
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Universitatsklinikum Charite, Campus Virchow Klinikum, Humboldt Universitat, Berlin
    Z Gastroenterol 39:145-51. 2001

Collaborators

Detail Information

Publications102 found, 100 shown here

  1. doi request reprint CD154, a marker of antigen-specific stimulation of CD4 T cells, is associated with response to treatment in patients with chronic HCV infection
    J F Möller
    Medizinische Klinik m S Hepatologie und Gastroenterologie, Charite Universitatsmedizin Berlin, CVK, Berlin Hepatologische Schwerpunktpraxis, Berlin, Germany
    J Viral Hepat 18:e341-9. 2011
    ..Our data indicate that CD154 as a marker of activation of CD4 T cells is a suitable tool for the analysis of T-cell responses in patients with HCV infection...
  2. pmc Isoforms of retinol binding protein 4 (RBP4) are increased in chronic diseases of the kidney but not of the liver
    Simone K Frey
    Institute of Nutritional Science, University of Potsdam, Potsdam Rehbrucke, Germany
    Lipids Health Dis 7:29. 2008
    ..RBP4 was determined by ELISA and apo- and holo-RBP4 by native polyacrylamide gel electrophoresis (PAGE). RBP4-L and RBP4-LL were analyzed after immunoprecipitation by mass spectrometry (MALDI-TOF-MS)...
  3. doi request reprint Tailored treatment for hepatitis C
    Thomas Berg
    Medical Department Hepatology and Gastroenterology, Charite, Campus Virchow Klinikum, Universitatsmedizin Berlin, Berlin, Germany
    Clin Liver Dis 12:507-28, vii-viii. 2008
    ..In contrast, patients who have a slow response have a high risk for relapse but seem to profit from extending treatment duration. This viral kinetically driven approach to tailor treatment is generally applicable to all genotypes...
  4. ncbi request reprint Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3
    Thomas Berg
    Charite Universitatsmedizin Berlin, Berlin, Germany
    Antivir Ther 13:17-22. 2008
    ..As in genotype 1 and 4 patients, response-guided therapy aims to optimize treatment outcomes for individuals, without compromising SVR rates...
  5. ncbi request reprint Distinct enzyme profiles in patients with cryptogenic cirrhosis reflect heterogeneous causes with different outcomes after liver transplantation (OLT): a long-term documentation before and after OLT
    Thomas Berg
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charite, Campus Virchow Klinikum, Humboldt Universitat zu Berlin, Germany
    Transplantation 74:792-8. 2002
    ..Sound information is lacking about the clinical presentation of cryptogenic cirrhosis and its outcome after orthotopic liver transplantation (OLT)...
  6. doi request reprint Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients
    Thomas Berg
    Universitatsklinikum Charite, Campus Virchow Klinikum, Universitatsmedizin Berlin, Berlin, Germany
    Hepatology 50:369-77. 2009
    ..The inferiority of the individualized protocol may be explained by the use of a less sensitive HCV RNA assay, and also by underestimation of the importance of baseline viremia...
  7. ncbi request reprint Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial
    Thomas Berg
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Universitatsklinikum Charite, Campus Virchow Klinikum, Humboldt Universitat, Berlin, Germany
    Hepatology 37:1359-67. 2003
    ....
  8. ncbi request reprint Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin
    Thomas Berg
    Universitatsklinikum Charite, Campus Virchow Klinikum, Universitatsmedizin Berlin, Germany
    Gastroenterology 130:1086-97. 2006
    ..The extension of treatment duration beyond 48 weeks is one possible strategy to address this problem...
  9. ncbi request reprint [Therapeutic challenges in viral hepatitis patients]
    A Bergk
    Medizinische Klinik m S Hepatologie und Gastroenterologie, Charite, Universitatsmedizin Berlin
    Dtsch Med Wochenschr 130:S218-20. 2005
  10. ncbi request reprint Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C
    T Berg
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Universitatsklinikum Charite, Campus Virchow Klinikum, Humboldt Universitat, Berlin
    Z Gastroenterol 39:145-51. 2001
    ..These data indicate, that even triple therapy with high-dose IFN alpha plus ribavirin and amantadine fails to improve significantly the response rates in IFN alpha-nonresponders...
  11. ncbi request reprint Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial
    T Berg
    Medizinische Klinik mit Schwerpunkt, Hepatologie und Gastroenterologie, Universitatsklinikum Charite, Humboldt Universitat, Berlin, Germany
    Liver 20:427-36. 2000
    ..Furthermore, we also examined whether short-term induction combination therapy followed by IFNalpha alone is more effective than monotherapy in mounting an initial as well as a sustained virological response...
  12. ncbi request reprint [Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patiens with response or no response]
    T Berg
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Universitatsklinikum Charite, Campus Virchow Klinikum, Humboldt Universitat, Germany
    Z Gastroenterol 38:881-6. 2000
    ....
  13. ncbi request reprint Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment
    T Berg
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Universitatsklinikum Charite, Campus Virchow Klinikum, Humboldt Universitat, Berlin, Germany
    Hepatology 32:1386-95. 2000
    ..2 of 35 [6%]; P =.045). Thus, NS5A appears to be functionally relevant in IFN-alpha-induced effector reactions...
  14. ncbi request reprint Occurrence of a novel DNA virus (TTV) infection in patients with liver diseases and its frequency in blood donors
    T Berg
    Medizinische Klinik mit Schwerpunkt Hepatologie Gastroenterologie, Universitatsklinikum Charite, Humboldt Universitat, Berlin, Germany
    J Med Virol 59:117-21. 1999
    ..A relevant hepatitis-inducing capacity of TTV, however, seems unlikely, considering the observation that in the majority of patients, TTV infection after OLT was not accompanied by graft hepatitis...
  15. ncbi request reprint Dynamics of GB virus C viremia early after orthotopic liver transplantation indicates extrahepatic tissues as the predominant site of GB virus C replication
    T Berg
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Berlin
    Hepatology 29:245-9. 1999
    ..However, one cannot exclude that host or viral factors exist that predispose GBV-C replication predominantly in the liver...
  16. pmc Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences
    M Pascu
    Medizinische Klinik m S Hepatologie und Gastroenterologie, Charite, Universitatsmedizin Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany
    Gut 53:1345-51. 2004
    ....
  17. ncbi request reprint Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy
    Thomas Berg
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Universitatsklinikum Charite, Campus Virchow Klinikum, Humboldt Universitat, Berlin, Germany
    Hepatology 37:600-9. 2003
    ..This algorithm recognizes 53.7% of nonresponders previously identified at week 24 of treatment...
  18. ncbi request reprint Pretransplant virological markers hepatitis C virus genotype and viremia level are not helpful in predicting individual outcome after orthotopic liver transplantation
    T Berg
    Department of Internal Medicine, Universitatsklinikum Charite, Campus Virchow Klinikum, Medizinische Fakultat der Humboldt Universitat zu Berlin, Germany
    Transplantation 66:225-8. 1998
    ..In the present study, the prognostic relevance of hepatitis C virus (HCV) genotypes and viremia for the development and severity of graft hepatitis was investigated...
  19. ncbi request reprint Significance of mycophenolate mofetil treatment in patients with HCV reinfection after liver transplantation: impact on clinical course and histologic damage
    M Bahra
    Department of Surgery, Charite Campus Virchow Klinikum, Humboldt University, Berlin, Germany
    Transplant Proc 34:2934-5. 2002
  20. ncbi request reprint Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy
    Florian van Bömmel
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charite Campus Virchow Klinikum, Universitatsmedizin Berlin, Berlin, Germany
    Hepatology 44:318-25. 2006
    ..No side effects were reported. In conclusion, these preliminary observations strongly suggest that TDF might be a highly effective rescue drug for HBV-infected patients with altered responsiveness to treatment with lamivudine and ADV...
  21. ncbi request reprint Association of TLR7 single nucleotide polymorphisms with chronic HCV-infection and response to interferon-a-based therapy
    E Schott
    Department of Hepatology and Gastroenterology, CVK, Charite Universitatsmedizin, Berlin, Germany
    J Viral Hepat 15:71-8. 2008
    ..Our results suggest that variations of TLR7 impair the immune response to HCV and imply a gender-specific effect of this X-chromosomal variation...
  22. ncbi request reprint Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection
    Tobias Mueller
    Charite, Campus Virchow Klinikum, Medizinische Klinik mit Schwerpunkt, Hepatologie und Gastroenterologie, Universitatsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
    J Hepatol 41:652-8. 2004
    ..We investigated whether the IL12B polymorphisms within the promoter region (4 bp insertion/deletion) and the 3'-UTR (1188-A/C), which have been reported to influence IL-12 synthesis, are associated with the outcome of HCV infection...
  23. ncbi request reprint Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis
    S Jonas
    Department of General Surgery, Humboldt University, Berlin, Germany
    Hepatology 33:1080-6. 2001
    ..Tumor diameter and number of nodules in correlation with the histopathologic grading were predictive of a vascular invasion only in HCC larger than 5 cm...
  24. ncbi request reprint Nosocomial transmission of hepatitis C virus from an anesthesiologist to three patients--epidemiologic and molecular evidence
    K Stark
    Robert Koch Institut Berlin, Berlin, Germany
    Arch Virol 151:1025-30. 2006
    ..HCV sequencing demonstrated that all four persons were infected by the same strain. The precise mode of transmission could not be elucidated but hygienic standards had been severely neglected...
  25. doi request reprint [Strategies for the prevention of hepatocellular carcinoma in the context of chronic viral hepatitis]
    E Schott
    Med Klinik m S Hepatologie und Gastroenterologie, Charite, CVK, Berlin
    Z Gastroenterol 46:69-80. 2008
    ..Due to its antiproliferative effects, the immunosuppressive drug sirolimus may play a role for secondary prevention of HCC following transplantation...
  26. ncbi request reprint Hepatitis-C patients have reduced growth hormone (GH) secretion which improves during long-term therapy with pegylated interferon-alpha
    Ursula Plockinger
    Interdisziplinäres Stoffwechsel Centrum, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
    Am J Gastroenterol 102:2724-31. 2007
    ..We therefore investigated prospectively basal and stimulated pituitary hormone secretion in 21 patients with chronic hepatitis C virus (HCV) infection before and during antiviral therapy...
  27. ncbi request reprint Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease
    Thomas Steinmuller
    Department of General, Visceral, and Transplant Surgery, Charite Campus Virchow, Humboldt University of Berlin, Berlin, Germany
    Hepatology 35:1528-35. 2002
    ..Based on our experience, hepatitis B patients, including those with active viral replication, should not be excluded from liver transplantation...
  28. doi request reprint Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient
    B Schlosser
    Department of Gastroenterology and Hepatology, Charite University Medicine, Campus Virchow Klinikum, Berlin, Germany
    J Hepatol 56:500-2. 2012
    ..Liver cirrhosis developed within 15 months and the patient died of septic shock. Based on phylogenetic analyses of the donor and recipient's HEV strains, we were able to prove that the occult HEV infection was transmitted via the graft...
  29. ncbi request reprint Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma
    Arne Scholz
    Department of Hepatology and Gastroenterology, CVK, Charite Universitatsmedizin Berlin, Berlin, Germany
    Am J Gastroenterol 102:2471-81. 2007
    ..Alpha-fetoprotein (AFP) serum levels are used for the screening for HCC, with limited success. We evaluated angiopoietin-2 as a serum marker in patients with cirrhosis and with HCC...
  30. doi request reprint Sexually transmitted infection with an immune-escape mutant hepatitis B virus (HBV) in an HBV-vaccinated individual with acute HIV-HCV infection
    P Ingiliz
    Medical Center for Infectious Diseases, Berlin, Germany
    J Int AIDS Soc 15:18432. 2012
    ..Despite a fairly high CD4 count, the transmission may have been promoted by a loss of immunity through an acute HIV infection. Clinicians need to be aware of the possibility of HBV infections with mutant viruses...
  31. ncbi request reprint Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance
    D Seehofer
    Department of General, Visceral and Transplant Surgery, Charite Campus Virchow, Humboldt University of Berlin, Germany
    Z Gastroenterol 40:795-9. 2002
    ..Due to viral escape mutations recurrence still occurs, but recently a combination prophylaxis with hepatitis B immunoglobuline plus lamivudine is evaluated in transplant centers in terms of a further reduction of recurrence rates...
  32. ncbi request reprint [Therapy of recurrent hepatitis B infection after liver transplantation. A retrospective analysis of 200 liver transplantations based on hepatitis B associated liver diseases]
    D Seehofer
    Klinik fUr Allgemein, Viszeral und Transplantationschirurgie, Humboldt Universitat zu Berlin
    Z Gastroenterol 38:773-83. 2000
    ..The result was a inferior graft survival. In the present retrospective analysis of the efficacy of hepatitis B therapy after liver transplantation was analysed retrospectively...
  33. ncbi request reprint Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation
    D Seehofer
    Department of General, Visceral, and Transplant Surgery, Campus Virchow, Humboldt University of Berlin, Germany
    Liver Transpl 7:976-82. 2001
    ..The combination of different antivirals diminished viral replication after lamivudine resistance. In the future, new antiviral agents, such as adefovir, might further expand therapeutic options...
  34. ncbi request reprint Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy)
    Marcus Bahra
    Klinik fUr Allgemein, Viszeral, und Transplantationschirurgie, Universitatsklinikum Charite, Campus Virchow Klinikum, Humboldt Universitat, Berlin, Germany
    Transplantation 83:351-3. 2007
    ..Sustained virologic response is associated with a deceleration of fibrosis progression and might therefore play a major role in prevention of graft cirrhosis in hepatitis C virus-infected liver graft recipients...
  35. ncbi request reprint Peginterferon alfa-2b plus ribavirin for the treatment of hepatitis C recurrence following combined liver and kidney transplantation
    Volker Schmitz
    Department of General, Visceral and Transplantation Surgery, Charite, Campus Virchow, Berlin, Germany
    Ann Transplant 12:22-7. 2007
    ....
  36. ncbi request reprint Outcome after liver re-transplantation in patients with recurrent chronic hepatitis C
    Marcus Bahra
    Klinik fUr Allgemein, Viszeral, und Transplantationschirurgie, Universitatsklinikum Charite, Campus Virchow Klinikum, Humboldt Universitat, Berlin, Germany
    Transpl Int 20:771-8. 2007
    ..This observational study may help select patients and identify the optimal time-point of liver retransplantation in ''Hepatitis C'' virus positive patients in the future...
  37. ncbi request reprint Influence of donor histology on outcome in patients undergoing transplantation for hepatitis C
    Marcus Bahra
    Klinik fUr Allgemein, Viszeral, und Transplantationschirurgie, Universitatsklinikum Charite, Campus Virchow Klinikum, Humboldt Universitat, Berlin, Germany
    Transplantation 84:144-8. 2007
    ..Donor age was defined as one of the most important predictors of outcome in these patients; however, the mechanism leading to more severe recurrent hepatitis has not yet been investigated...
  38. ncbi request reprint Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects
    Martin Schaefer
    Charite Universitatsmedizin Berlin, Klinik und Poliklinik für Psychiatrie und Psychotherapie Campus Charité Mitte, Berlin, Germany
    Hepatology 46:991-8. 2007
    ....
  39. ncbi request reprint Association of CTLA4 single nucleotide polymorphisms with viral but not autoimmune liver disease
    Eckart Schott
    Department of Hepatology and Gastroenterology, Charite University Hospital Berlin, Berlin, Germany
    Eur J Gastroenterol Hepatol 19:947-51. 2007
    ..In reverse form, CTLA4 variations are associated with chronic infections such as chronic hepatitis B...
  40. ncbi request reprint Increased mortality after liver transplantation for hepatocellular carcinoma in hepatitis B-associated cirrhosis
    Sven Jonas
    Department of General, Visceral, and Transplantation Surgery, Charite Campus Virchow Klinikum, Humboldt University Berlin, Augustenburger Platz 1, 13353, Berlin, Germany
    Transpl Int 16:33-6. 2003
    ..22%; P<0.05). This difference was due to unspecific causes, not to tumor recurrence or re-infection. These findings may be indicative of a more complicated course in patients suffering from hepatitis B in general...
  41. doi request reprint Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection
    Juliane Halangk
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Germany
    J Hepatol 49:339-45. 2008
    ..In 277 patients with hepatitis C, two C5 SNPs, rs17611 and rs2300929, have been associated with advanced fibrosis...
  42. doi request reprint Antiviral treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon
    Sven C Schmidt
    Klinik fUr Allgemein, Viszeral, und Transplantationschirurgie, Charite Campus Virchow Klinikum, Universitatsmedizin Berlin, Berlin, Germany
    Dig Dis Sci 55:2063-9. 2010
    ..The recurrence of hepatitis C virus (HCV) after liver transplantation (OLT) leads to recurrent cirrhosis in up to 40% of patients...
  43. doi request reprint Low-density lipoprotein receptor variants are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection
    Andreas Mas Marques
    Robert Koch Institut, Berlin, Germany
    Infect Genet Evol 9:847-52. 2009
    ..1413G>A heterozygosity (33.0% vs. 46.1%, p=0.023). The data indicate that LDLR alterations are correlated with response to interferon-based combination therapy and with self-limitation of HCV 1 infection...
  44. doi request reprint Evaluation of angiotensinogen c.1-44G>A and p.M268T variants as risk factors for fibrosis progression in chronic hepatitis C and liver diseases of various etiologies
    Juliane Halangk
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charite Universitatsmedizin Berlin, Berlin, Germany
    Genet Test Mol Biomarkers 13:407-14. 2009
    ..A functional genetic alteration in the human AGT promoter (c.1-44G>A) has been linked to accelerated progression of fibrosis in hepatitis C virus infection...
  45. doi request reprint Chances and limitations of non-invasive tests in the assessment of liver fibrosis in liver transplant patients
    Carsten Kamphues
    Department of General, Visceral and Transplantation Surgery, Universitatsklinikum Charite, Humboldt Universitat, Berlin, Germany
    Clin Transplant 24:652-9. 2010
    ..Both serum markers AST-to-platelet ratio index and FIB-4 are not feasible to assess liver fibrosis in liver transplant patients...
  46. doi request reprint Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues
    Florian van Bömmel
    Medizinische Klinik m S Hepatologie und Gastroenterologie Charité, Campus Virchow Klinikum, Universitatsmedizin Berlin, Germany
    Hepatology 51:73-80. 2010
    ..CONCLUSION: TDF monotherapy induced a potent and long-lasting antiviral response in NA-experienced patients with previous treatment failure. Our data may have implications for current add-on strategies...
  47. doi request reprint Viscoelasticity-based staging of hepatic fibrosis with multifrequency MR elastography
    Patrick Asbach
    Department of Radiology, Charite Universitatsmedizin Berlin, Chariteplatz 1, Berlin, Germany
    Radiology 257:80-6. 2010
    ..To analyze the dynamics of the shear modulus of the liver to assess the optimal driving frequency and to determine the diagnostic accuracy of generalized frequency-independent elasticity cutoff values for staging hepatic fibrosis...
  48. doi request reprint Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation
    Dennis Eurich
    Department of General, Visceral, and Transplant Surgery, Charite, Campus Virchow, Berlin, Germany
    Liver Transpl 17:289-98. 2011
    ..G-allele might serve as a marker for graft inflammation and as a predictor for unfavorable antiviral therapy outcome in HCV-re-infected LT-population...
  49. ncbi request reprint Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin
    Ulf Neumann
    Klinik fUr Allgemein, Viszeral, und Transplantationschirurgie, Universitatsklinikum Charite, Campus Virchow Klinikum, Humboldt Universitat, Berlin, Germany
    Transplantation 82:43-7. 2006
    ....
  50. doi request reprint Quantitative detection and typing of hepatitis D virus in human serum by real-time polymerase chain reaction and melting curve analysis
    Joerg Hofmann
    Institute of Medical Virology, Helmut Ruska Haus, Charite Universitatsmedizin, D 10117 Berlin, Germany
    Diagn Microbiol Infect Dis 67:172-9. 2010
    ..Therefore, this assay is useful for monitoring of antiviral treatment and molecular epidemiologic studies of HDV distribution...
  51. ncbi request reprint Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection
    Florian van Bömmel
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charite, Universitatsmedizin Berlin, Campus Virchow, Berlin, Germany
    Hepatology 40:1421-5. 2004
    ..In conclusion, tenofovir may become an effective alternative for the treatment of patients with lamivudine-resistant HBV infection...
  52. ncbi request reprint Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C
    Martin Schaefer
    Department of Psychiatry, Charite University Medicine Berlin, Campus Charite Mitte, Schumannstr 20 21, D 10117 Berlin, Germany
    J Hepatol 42:793-8. 2005
    ..We prospectively studied the efficacy of a pre-emptive treatment with the antidepressant citalopram to prevent depression during hepatitis C treatment with pegylated IFN-alpha-2b plus ribavirin...
  53. ncbi request reprint Prevention of hepatitis B recurrence after liver transplantation
    Daniel Seehofer
    Department of General, Visceral, and Transplantation Surgery, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
    Transplantation 80:S120-4. 2005
    ..In the following, current strategies of reinfection prophylaxis and future perspectives are reviewed...
  54. ncbi request reprint MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course
    Marcus Bahra
    Medizinischa Klinik mit Schwerpunht, Hepatologie, Gastroentorologie, Universitätsklinikum Charité and Campus Virchow Klinikum, Humboldt Universitat, Berlin, Germany
    Am J Transplant 5:406-11. 2005
    ..MMF in combination with CNI taper showed a positive effect on fibrosis progression, graft inflammation and ALT levels and may improve the clinical course of HCV after OLT, however, the antiviral properties of MMF are still unconfirmed...
  55. ncbi request reprint Fibrosis progression after liver transplantation in patients with recurrent hepatitis C
    Ulf P Neumann
    Klinik fUr Allgemein, Viszeral, und Transplantationschirurgie, Universitatsklinikum Charite, Campus Virchow Klinikum, Humboldt Universitat zu Berlin, D 13353 Berlin, Germany
    J Hepatol 41:830-6. 2004
    ....
  56. ncbi request reprint Influence of donor/recipient HLA-matching on outcome and recurrence of hepatitis C after liver transplantation
    Jan Michael Langrehr
    Department of Surgery, Charite, Campus Virchow Clinic, Humboldt University, Berlin, Germany
    Liver Transpl 12:644-51. 2006
    ....
  57. ncbi request reprint Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up
    Ulf P Neumann
    Klinik fUr Allgemein, Viszeral, und Transplantationschirurgie, Universitatsklinikum Charite, Campus Virchow Klinikum, Humboldt Universitat, Berlin, Germany
    Transplantation 77:226-31. 2004
    ..However, there are still no clear predictors for severe recurrence. The aim of this study was to examine the 10-year outcome and risk factors for graft failure caused by HCV recurrence...
  58. pmc A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis
    Heiko Witt
    Department of Hepatology and Gastroenterology, Charite University Hospital, Augustenburger Platz 1, 13353 Berlin, Germany
    Nat Genet 38:668-73. 2006
    ..In conclusion, the G191R variant of PRSS2 mitigates intrapancreatic trypsin activity and thereby protects against chronic pancreatitis...
  59. ncbi request reprint Risk factors for the acquisition of hepatitis C
    A Bergk
    Department of Medicine, Charite Medical Center, Virchow Hospital, Medical School of the Humboldt University, Berlin, Germany
    Minerva Gastroenterol Dietol 51:7-14. 2005
    ..This article aims to summarize recent advances in understanding transmission pathways and outlines future prevention strategies...
  60. doi request reprint [Extrahepatic manifestations of chronic hepatitis C virus infection]
    K P Puchner
    Medizinische Klinik m S Hepatologie und Gastroenterologie, Charite, Campus Virchow Klinikum, Universitatsmedizin Berlin
    Z Gastroenterol 47:446-56. 2009
    ..Immunosuppressive drugs, plasmapheresis and lately rituximab are counted among therapies that can be applied complementarly or alternatively to the antiviral therapy...
  61. ncbi request reprint Persistence of a sexually transmitted highly resistant HIV-1: pol quasispecies evolution over 33 months in the absence of treatment
    Stefan Neifer
    Medical Laboratory Prenzlauer Berg, Berlin, Germany
    AIDS 20:2231-3. 2006
    ..Persistence of the replication-competent resistant HIV increases its potential to spread further and strengthens the importance of resistance testing in newly infected patients...
  62. doi request reprint HIV-1 drug resistance testing at low viral load may help to differentiate between ongoing replication and release from reservoirs
    M Obermeier
    Mikrobiologisches Infektiologiezentrum Berlin, Berlin, Germany
    J Int AIDS Soc 15:18178. 2012
    ..Viral loads above 100,000 cop/ml seems here to be a sign of missing selective pressure due to incompliance of the patients and thus no drug resistance was observed...
  63. doi request reprint Activation and inflammation markers in HIV-1-infected patients in dependency of treatment strategies
    R Ehret
    Mikrobiologisches Infektiologiezentrum Berlin, Berlin, Germany
    J Int AIDS Soc 15:18293. 2012
    ..A possible reason could be a pre-selection bias either for NNRTI-based or PI-based regimens. Additional data is acquired to perform longitudinal analysis to gain further insight...
  64. doi request reprint Impaired insulin sensitivity as an underlying mechanism linking hepatitis C and posttransplant diabetes mellitus in kidney recipients
    S Baid-Agrawal
    Division of Nephrology and Medical Intensive Care, Department of Medicine, Berlin, Germany
    Am J Transplant 9:2777-84. 2009
    ....
  65. ncbi request reprint Liver transplantation in hepatitis B patients with preoperative resistance formation during lamivudine treatment
    D Seehofer
    Department of General Surgery, Charite Campus Virchow, Humboldt University of Berlin, Berlin, Germany
    Transplant Proc 34:2274-5. 2002
  66. doi request reprint Relevance of endotoxin receptor CD14 and TLR4 gene variants in chronic liver disease
    Thomas von Hahn
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Germany
    Scand J Gastroenterol 43:584-92. 2008
    ..Our objective was to analyze these two variations...
  67. doi request reprint High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy
    M Biermer
    Sektion Hepatologie, Klinik und Poliklinik für Gastroenterologie und Rheumatologie, Universitatsklinikum Leipzig, Leipzig, Germany
    J Viral Hepat 19:547-53. 2012
    ..These preliminary findings may stimulate further studies to evaluate more refined therapeutic strategies...
  68. ncbi request reprint N-terminal pro-B-type natriuretic peptide (NT-proBNP) in HIV-1 infected individuals on HAART
    T Berg
    Medizinisches Labor Dr Berg, Berlin, Germany
    Eur J Med Res 12:152-60. 2007
    ..NT-proBNP has been shown to represent an indicator of cardiac function...
  69. ncbi request reprint Percutaneous transjugular direct porto-caval shunt in patients with Budd-Chiari syndrome
    A Quateen
    Department of Diagnostic and Interventional Radiology, Charite Campus Virchow Clinic, Universitatsmedizin Berlin, 13353 Berlin, Germany
    Cardiovasc Intervent Radiol 29:565-70. 2006
    ..Future studies in larger patient groups should investigate if the patency of transcaval TIPSS with long transhepatic shunt segments is similar compared to conventional TIPSS via the hepatic vein...
  70. ncbi request reprint Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
    George K K Lau
    Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong SAR, China
    N Engl J Med 352:2682-95. 2005
    ....
  71. ncbi request reprint GNB3 C825T polymorphism and response to interferon-alfa/ribavirin treatment in patients with hepatitis C virus genotype 1 (HCV-1) infection
    Christoph Sarrazin
    Universitatsklinikum des Saarlandes, Klinik fur Innere Medizin II, Kirrberger Str 41, D 66421 Homburg Saar, Germany
    J Hepatol 43:388-93. 2005
    ..The G protein beta3 subunit (GNB3) C825T polymorphism has been shown to determine immune cell functions in vitro. We investigated the association of GNB3 genotypes with treatment response in HCV-infected patients...
  72. doi request reprint Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41
    Christoph S Klade
    Intercell AG, Vienna, Austria
    Gastroenterology 134:1385-95. 2008
    ..We aimed to investigate whether IC41 is able to induce HCV-specific T-cell responses also in chronic hepatitis C patients...
  73. ncbi request reprint Gender-dependent association of CTLA4 polymorphisms with resolution of hepatitis C virus infection
    Eckart Schott
    Department of Hepatology and Gastroenterology, CVK, Charite Universitatsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
    J Hepatol 46:372-80. 2007
    ..We investigated whether CTLA4 single nucleotide polymorphisms are associated with the resolution of infection or with the course of disease...
  74. ncbi request reprint Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C
    Michael von Wagner
    Universitatsklinikum des Saarlandes, Homburg Saar, Germany
    Gastroenterology 129:522-7. 2005
    ..Whether shorter treatment durations are possible for these patients without compromising sustained virologic response rates is unknown...
  75. ncbi request reprint Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials
    Alessandra Mangia
    Division of Gastroenterology, Ospedale Casa Sollievo Sofferenza, IRCCS, San Giovanni Rotondo 71013, Italy
    J Hepatol 40:478-83. 2004
    ..We performed a meta-analysis of the individual patient's data from previous studies...
  76. doi request reprint Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection
    Michael von Wagner
    Johann Wolfgang Goethe Universitat, Frankfurt, Main, Germany
    Hepatology 48:1404-11. 2008
    ..01). However, adverse events and laboratory abnormalities were similar between both groups. Per-protocol analysis revealed similar sustained virological response rates in both treatment groups (53% versus 55%)...
  77. ncbi request reprint Reactivation of viral replication after replacement of tenofovir by adefovir
    Florian van Bömmel
    Hepatology 42:239-40. 2005
  78. doi request reprint No role of matrixmetalloproteinase-3 genetic promoter polymorphism 1171 as a risk factor for cirrhosis in alcoholic liver disease
    Felix Stickel
    Institute of Clinical Pharmacology, University of Berne, Switzerland
    Alcohol Clin Exp Res 32:959-65. 2008
    ..We tested whether a functional promoter polymorphism in the gene encoding matrix metalloproteinase-3 (MMP-3; 1171 5A/6A) was associated liver cirrhosis in alcoholics...
  79. ncbi request reprint Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection
    Yves Horsmans
    Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Unit de Pharmacologie Clinique, Brussels, Belgium
    Hepatology 42:724-31. 2005
    ..In conclusion, systemic administration of the selective TLR7 agonist isatoribine resulted in dose-dependent changes in immunologic biomarkers and a statistically significant antiviral effect with relatively few and mild side effects...
  80. ncbi request reprint Impact of in vivo complement activation and cryoglobulins on graft outcome of HCV-infected renal allograft recipients
    Stefan M Weiner
    Department of Medicine, Marienhospital, Ruhr University Bochum, Hoelkeskampring 40, Herne, Germany
    Clin Transplant 18:7-13. 2004
    ..We examined whether cryoglobulinemia and complement turnover is associated with HCV infection in renal transplant recipients and whether this has an adverse effect on graft outcome...
  81. ncbi request reprint Effects of the CCR5-Delta32 mutation on antiviral treatment in chronic hepatitis C
    Golo Ahlenstiel
    Medizinische Klinik u Poliklinik I, Allgemeine Innere Medizin, Universitat Bonn, Sigmund Freud Strasse 25, D 53105, Bonn, Germany
    J Hepatol 39:245-52. 2003
    ..The CC-chemokine receptor (CCR) 5-Delta32 mutation may predispose to chronic liver disease and high level viremia in hepatitis C. However, it is unclear whether CCR5-Delta32 also affects the response to antiviral treatment...
  82. ncbi request reprint Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial
    Bernd Kronenberger
    Department of Medicine I, Johann Wolfgang Goethe University Medical Center, Frankfurt M, Germany
    Eur J Gastroenterol Hepatol 19:639-46. 2007
    ..The aim of this study was to investigate whether amantadine reduces deterioration of quality of life in patients with chronic hepatitis C during and after treatment with interferon-alpha (IFN-alpha) and ribavirin...
  83. ncbi request reprint Apolipoprotein E4 allele is associated with poor treatment response in hepatitis C virus (HCV) genotype 1
    Tobias Mueller
    Hepatology 38:1592; author reply 1592-3. 2003
  84. ncbi request reprint The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients
    Golo Ahlenstiel
    Department of Internal Medicine I, University of Bonn, Sigmund Freud Street 25, 53105 Bonn, Germany
    J Hepatol 47:348-55. 2007
    ..The G protein beta3 unit (GNB3) C825T polymorphism has been shown to affect treatment response in HCV mono-infection. Here, we analyzed the impact of the GNB3 genotype in the context of HCV/HIV co-infection...
  85. ncbi request reprint A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection
    Eckart Schott
    Department of Hepatology and Gastroenterology, CVK, Charite Universitatsmedizin Berlin, Germany
    J Hepatol 47:203-11. 2007
    ..Since HCV is an RNA virus, a role for TLR7 in the immune response against HCV is likely. No systematic analysis of TLR7 single nucleotide polymorphisms (SNPs) has been published...
  86. ncbi request reprint Haplotype-tagging RANTES gene variants influence response to antiviral therapy in chronic hepatitis C
    Hermann E Wasmuth
    Department of Medicine III, University Hospital Aachen, Aachen University, Aachen, Germany
    Hepatology 40:327-34. 2004
    ..In conclusion, RANTES haplotypes might contribute to the polygenic interaction between HCV and the host immune system and could help to risk stratify patients prior to antiviral therapy...
  87. ncbi request reprint Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection
    Guenther Schmutz
    Center for HIV and Hepatogastroenterology, Grafenberger Allee 128a, 40237 Duesseldorf, Germany
    AIDS 20:1951-4. 2006
    ..It is unknown to date whether combination therapy with lamivudine plus tenofovir could be superior to sequential therapy with tenofovir after the occurrence of lamivudine resistance...
  88. ncbi request reprint Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C?
    Thomas Berg
    Hepatology 39:1456-7; author reply 1457-8. 2004
  89. ncbi request reprint CC chemokine receptor 5 delta32 polymorphism in two independent cohorts of hepatitis C virus infected patients without hemophilia
    Hermann E Wasmuth
    Department of Medicine III, University Hospital Aachen, Aachen University RWTH, Pauwelsstrasse 30, 52074 Aachen, Germany
    J Mol Med (Berl) 82:64-9. 2004
    ....
  90. ncbi request reprint Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C
    Markus Cornberg
    Department of Gastroenterology, Hepatology, and Endocrinology, Medizinische Hochschule Hannover, Carl Neuberg Strasse 1, D 30625 Hannover, Germany
    J Hepatol 37:843-7. 2002
    ..The present study is a pilot study evaluating the efficacy and safety of combination therapy with interferon alfa-2a and MMF in interferon alfa nonresponder patients...
  91. ncbi request reprint Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation
    Florian van Bömmel
    Gastroenterology 124:586-7. 2003
  92. ncbi request reprint Prediction of spontaneous viral clearance in acute hepatitis C by viral load measurements
    Thomas Berg
    Hepatology 37:1495-6; author reply 1496. 2003
  93. ncbi request reprint The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection
    Hermann E Wasmuth
    Medical Department III, University Hospital Aachen, Pauwelsstrasse 30, D 52057 Aachen, Germany
    J Hepatol 48:208-15. 2008
    ..The chemokine receptor CX3CR1 and its specific ligand fractalkine (CX3CL1) are known to modulate inflammatory and fibroproliferative diseases. Here we investigate the role of CX3CR1/fractalkine in HCV-induced liver fibrosis...
  94. ncbi request reprint Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C
    John G McHutchison
    Duke University and Duke Clinical Research Institute, Durham, NC 27705, USA
    N Engl J Med 357:2227-36. 2007
    ..We evaluated its ability to increase platelet counts and facilitate treatment for hepatitis C virus (HCV) infection in patients with thrombocytopenia associated with HCV-related cirrhosis...
  95. ncbi request reprint Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferon alpha-2a (40KD) plus ribavirin
    Eric Snoeck
    Exprimo NV, Mechelen, Belgium
    Liver Int 28:61-71. 2008
    ..Currently, the approved dosage of ribavirin has not been studied in patients with 'normal' alanine aminotransferase (ALT) levels...
  96. ncbi request reprint Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients
    Jacob Nattermann
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    Hepatology 46:1016-25. 2007
    ..1; P = 0.004). This effect corresponds to the in vitro observation that in HCV core-transfected HUH7 cells, IL-6 overcomes the HCV core-mediated inhibition of STAT3 activation...
  97. ncbi request reprint Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study
    Johannes Wiegand
    Department of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Hannover, Germany
    Hepatology 43:250-6. 2006
    ..The high number of dropouts underlines the importance of thorough patient selection and close monitoring during therapy. Thus, future studies should identify factors predicting spontaneous viral clearance to avoid unnecessary therapy...
  98. doi request reprint Evaluation of the transforming growth factor beta1 codon 25 (Arg-->Pro) polymorphism in alcoholic liver disease
    Christoph H Osterreicher
    Department of Medicine, University of California, San Diego, Leichtag Building, Room 349 I, 9500 Gilman Drive, 0702, La Jolla, CA 92093 0702, USA
    Cytokine 42:18-23. 2008
    ..Its contribution to the progression of ALD has not been investigated sufficiently so far...
  99. ncbi request reprint Omega-3 fatty acids alleviate chemically induced acute hepatitis by suppression of cytokines
    Christoph Schmöcker
    Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Hepatology 45:864-9. 2007
    ..CONCLUSION: The results of this study offer evidence for an inflammation dampening effect of omega-3 polyunsaturated fatty acids in the context of liver inflammation...
  100. doi request reprint First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome
    Johannes Kapeller
    Department of Human Molecular Genetics, University of Heidelberg, Im Neuenheimer Feld 366, 69120 Heidelberg, Germany
    Hum Mol Genet 17:2967-77. 2008
    ..This is the first example indicating micro RNA-related expression regulation of a serotonin receptor gene with a cis-regulatory variant affecting this regulation and appearing to be associated with female IBS-D...
  101. ncbi request reprint Induction of interleukin-6 by hepatitis C virus core protein in hepatitis C-associated mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma
    Georg Feldmann
    Department of Internal Medicine 1, University of Bonn, Bonn, Germany
    Clin Cancer Res 12:4491-8. 2006
    ..To clarify this issue, we studied whether recognition of hepatitis C virus (HCV) proteins by PRR is involved in the pathogenesis of HCV-associated MC or B-NHL...